

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended): A method for inhibiting the activation of telomerase, comprising ~~which is selected from the following group:~~
 - (i) ~~a method for inhibiting the activation of telomerase, comprising~~ inhibiting the binding of MAPKAPK3 (mitogen-activated protein kinase-activated protein kinase-3) to TERT (telomerase reverse transcriptase); ~~and or~~
 - (ii) ~~a method for inhibiting the activation of telomerase, comprising~~ inhibiting the phosphorylation of TERT by active MAPKAPK3.
2. (Currently amended): A method for inhibiting the activation of telomerase according to claim 1, comprising inhibiting the binding of MAPKAPK3 (mitogen-activated protein kinase-activated protein kinase-3) to TERT (telomerase reverse transcriptase).
3. (Currently amended): A method for inhibiting telomerase activity, comprising ~~using~~ utilizing the method for inhibiting the activation of telomerase according to claim 1 ~~or 2~~.
4. (Original): A method for inhibiting telomerase activity by an inactive variant of MAPKAPK3 (mitogen-activated protein kinase-activated protein kinase-3), wherein the variant is a variant that binds to TERT (telomerase reverse transcriptase).
5. (Original): The method for inhibiting telomerase activity according to claim 4, wherein the inactive variant of MAPKAPK3 (mitogen-activated protein kinase-activated protein kinase-3) is a protein shown by the amino acid sequence set forth in SEQ ID NO: 6 in the sequence listing.
6. (Currently amended): A method for preventing and/or treating a disease attributable to

the enhanced telomerase activity, comprising utilizing ~~using the method for inhibiting the activation of telomerase according to claim 1 or 2 and/or~~ the method for inhibiting telomerase activity according to claim 3 ~~any one of claims 3 to 5~~.

7. (Original): The method for preventing and/or treating a disease attributable to the enhanced telomerase activity according to claim 6, wherein the disease attributable to the enhanced telomerase activity is a cancer disease.

8. (Currently amended): The method for preventing and/or treating a disease attributable to the enhanced telomerase activity according to claim 7, wherein the cancer disease is ~~any of~~ breast cancer, renal cell carcinoma, acute leukemia, glia cell carcinoma, prostatic cancer, neuroepithelial carcinoma, squamous cell carcinoma, liver cell carcinoma, prostatic cancer, ~~and~~ or non-small cell lung cancer.

9. (Original): The method for preventing and/or treating a disease attributable to the enhanced telomerase activity according to claim 7, wherein the cancer disease is a breast cancer disease.

10. (Currently amended): A method of identifying ~~a compound~~ the agent of claim 13, that inhibits the binding of MAPKAPK3 (mitogen-activated protein kinase-activated protein kinase-3) to TERT (telomerase reverse transcriptase), wherein the method comprises contacting a compound with MAPKAPK3 and/or TERT under a condition allowing the compound to interact with MAPKAPK3 and/or the TERT, introducing a system using a signal and/or a marker that is generated by the binding of MAPKAPK3 to TERT, and detecting the presence, absence or change of the signal and/or the marker, thereby determining whether the compound inhibits the binding of MAPKAPK3 to the TERT.

11. (Currently amended): A method of identifying ~~a compound~~ the agent of claim 13, that

inhibits the phosphorylation of TERT (telomerase reverse transcriptase) by active MAPKAPK3 (mitogen-activated protein kinase-activated protein kinase-3), wherein the method comprises contacting a compound with active MAPKAPK3 and/or TERT under a condition allowing the compound to interact with active MAPKAPK3 and/or TERT, introducing a system using a signal and/or a marker that is generated by the phosphorylation of TERT by active MAPKAPK3, detecting the presence, absence or change of the signal and/or the marker, thereby determining whether the compound inhibits the phosphorylation of TERT by active MAPKAPK3.

12. (Canceled)

13. (Currently amended): An agent for inhibiting the activation of telomerase or inhibiting telomerase activity, comprising which is selected from the following group:

~~(i) an agent for inhibiting the activation of telomerase, comprising~~ at least one compound that inhibits the binding of MAPKAPK3 (mitogen-activated protein kinase-activated protein kinase-3) to TERT (telomerase reverse transcriptase); ~~and~~ or

~~(ii) an agent for inhibiting the activation of telomerase, comprising~~ at least one compound that inhibits the phosphorylation of TERT by active MAPKAPK3.

14. (Canceled)

15. (Canceled)

16. (Original): An agent for inhibiting telomerase activity comprising an inactive variant of MAPKAPK3 (mitogen-activated protein kinase-activated protein kinase-3), wherein the variant is a variant that binds to TERT (telomerase reverse transcriptase).

17. (Original): The agent for inhibiting telomerase activity comprising an inactive variant of MAPKAPK3 (mitogen-activated protein kinase-activated protein kinase-3) according to claim 16, wherein the inactive variant of MAPKAPK3 is a protein shown by the amino acid sequence

set forth in SEQ ID NO: 6 in the sequence listing.

18. (Canceled)

19. (Canceled)

20. (Canceled)

21. (Canceled)

22. (Canceled)

23. (Original): A reagent kit, comprising at least one selected from the group consisting of MAPKAPK3 (mitogen-activated protein kinase-activated protein kinase-3), a polynucleotide encoding MAPKAPK3, a vector containing the polynucleotide, and a transformant containing the vector; and at least one selected from the group consisting of TERT (telomerase reverse transcriptase), a polynucleotide encoding TERT, a vector containing the polynucleotide, and a transformant containing the vector.